Clinical experience with doxazosin in general medical practice in New Zealand
- 31 January 1991
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 121 (1) , 323-328
- https://doi.org/10.1016/0002-8703(91)90866-g
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Stratifying the patient at risk from coronary disease: New insights from the framingham heart studyAmerican Heart Journal, 1990
- Review of the effects of doxazosin, a new selective alpha1-adrenergic inhibitor, on lipoproteins in patients with essential hypertensionThe American Journal of Medicine, 1989
- Background and design of the new U.S. trial on diet and drug treatment of “mild” hypertension (TOMHS)The American Journal of Cardiology, 1987
- Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertensionThe American Journal of Cardiology, 1987
- SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MENThe Lancet, 1986
- The antihypertensive effects of doxazosin: a clinical overview.British Journal of Clinical Pharmacology, 1986
- Epidemiology of coronary heart disease: The Framingham studyThe American Journal of Medicine, 1984